Navigation Links
FDA Permits Marketing of a System to Repair Failed, Problematic Fix for Aortic Aneurysms
Date:11/21/2011

eview of data from 154 patients who were implanted with 810 EndoStaples. Patients were monitored with routine followup CT scans. After a year, none of the EndoStaples had fractured and no patients experienced endograft movement (migration); one subject needed an additional intervention to address an endoleak.

The Aptus EndoStapling System is for use in patients whose endovascular grafts have moved, exhibit endoleaks, or are at risk for these complications and additional intervention is needed to reattach the graft and seal off the aneurysm.

The Aptus EndoStapling System is manufactured by Aptus Endosystems Inc. of Sunnyvale, Calif.

For more information:
FDA: Medical Devices
http://www.fda.gov/MedicalDevices/default.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Permits Marketing of First Test to Help Diagnose Dengue Fever
2. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
3. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
6. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
7. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
11. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)...  Boston Scientific Corporation (NYSE: BSX ) ... quarter ended March 31, 2015, compared to the ... to $1.800 billion.  This represents 6 percent operational ... and flat revenue on a reported basis, all ... achieved adjusted earnings per share of $0.21 for ...
(Date:4/28/2015)... PARSIPPANY, N.J. and INDIANAPOLIS , ... who undergo an angioplasty procedure and receive a heart stent ... help prevent a heart attack, a blood clot in their ... survey conducted by Harris Poll found that 52 percent of ... missed taking or changed the way they take their prescribed ...
(Date:4/28/2015)... April 28, 2015  Shares of Celladon Corp. (NASDAQ: ... yesterday following the announcement of poor drug trial results of ... gene therapy agent, MYDICAR.  The selloff may be warranted ... company at bargain basement prices. An analyst ... overview, current pipeline, financial review, analyst summary, valuation, and ...
Breaking Medicine Technology:Boston Scientific Announces Results for First Quarter 2015 2Boston Scientific Announces Results for First Quarter 2015 3Boston Scientific Announces Results for First Quarter 2015 4Boston Scientific Announces Results for First Quarter 2015 5Boston Scientific Announces Results for First Quarter 2015 6Boston Scientific Announces Results for First Quarter 2015 7Boston Scientific Announces Results for First Quarter 2015 8Boston Scientific Announces Results for First Quarter 2015 9Boston Scientific Announces Results for First Quarter 2015 10Boston Scientific Announces Results for First Quarter 2015 11Boston Scientific Announces Results for First Quarter 2015 12Boston Scientific Announces Results for First Quarter 2015 13Boston Scientific Announces Results for First Quarter 2015 14Boston Scientific Announces Results for First Quarter 2015 15Boston Scientific Announces Results for First Quarter 2015 16Boston Scientific Announces Results for First Quarter 2015 17Boston Scientific Announces Results for First Quarter 2015 18Boston Scientific Announces Results for First Quarter 2015 19Boston Scientific Announces Results for First Quarter 2015 20Boston Scientific Announces Results for First Quarter 2015 21Boston Scientific Announces Results for First Quarter 2015 22Boston Scientific Announces Results for First Quarter 2015 23Boston Scientific Announces Results for First Quarter 2015 24Boston Scientific Announces Results for First Quarter 2015 25Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 2Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 4Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 5Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 6Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 7Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 8Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 9Examining what's Left after MYDICAR Drug Trial Ends In Failure; Celladon Corp. Analyst Report Issued by BrokerBank Securities, Inc. 2
... Knopp Neurosciences Inc. ("Knopp"),announced that the U.S. ... Development has granted orphan drug designation to ... (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... studies to evaluate the safety,tolerability and pharmacokinetics ...
... on stringent endpoint of clinical ... PHILADELPHIA, Oct. 15 An analysis of data to,be ... Scientific Meeting found that Asacol, dosed at 2.4 g/day, ... active,ulcerative colitis (UC). The analysis was based on data ...
Cached Medicine Technology:Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 2New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 3New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients 4
(Date:4/28/2015)... 28, 2015 The buyer power score ... of 5, indicating a medium level of buyer power ... suppliers have equal power during negotiations. One factor helping ... purchasing a health insurance policy from an insurance carrier ... buyers can choose to self-fund their own policy or ...
(Date:4/28/2015)... St. Louis, Missouri (PRWEB) April 28, 2015 ... report that delves into the reality problem Americans ... of the population will need long-term care services as ... will need such care. , In the report, ... from organizations such as the American Health Care Association ...
(Date:4/28/2015)... OsteoRemedies®, LLC, Memphis, TN, offers ... of infected hip and knee arthroplasty. ... pre-formed, pre-loaded spacer with Gentamicin Antibiotics, for consistent ... Combined with a consistent process for polishing ... approved for temporary use for up to 180 ...
(Date:4/28/2015)... 2015 Enrollment in programs designed ... 2.2 million in April, according to the editors ... Medicare-Medicaid Dual Eligibles Database , an online subscription ... the dual-eligible community. This is a 14% increase ... initiatives in January, but only covers about a ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 The PracticeMatch ... from 5:00 to 8:00 pm at the Sheraton Colonial Boston ... 50 hospitals, clinics and groups with career opportunities will be ... Attendees will enjoy free hors d’oeuvres and raffle prize drawings. ... says “Boston is an ideal location to hold a ...
Breaking Medicine News(10 mins):Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Enrollment in Duals Programs Increases 14%, New AIS Database Finds 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 3
... REFORM IMPLEMENTATION RECOMMENDS WAYS TO ENSURE ACCESS TO AFFORDABLE ... Full-Year Coverage, Combined Small Business and Individual Health Insurance ... New York, NY, May 19, 2011Modifications to ... and subsidies provided under the Affordable Care Act remain ...
... , WEDNESDAY, May 18 (HealthDay News) -- Long-term ... colon cancers in women with a high risk of breast ... drinking and physical activity affected the risk of several common ... because of family history of breast cancer, age and other ...
... , WEDNESDAY, May 18 (HealthDay News) -- Rep. Gabrielle Giffords, ... assassin, will undergo surgery Wednesday in Houston to replace the ... shooting, according to the Associated Press . This ... days after the three-term Democratic congresswoman from Arizona traveled to ...
... (HealthDay News) -- End-of-life care for older people with advanced ... Canadian province of Ontario, a new study says. U.S. ... much more use of hospital and emergency room services, according ... the Ontario Cancer Registry. The information was collected from people ...
... Rochester Medical Center researchers have pinpointed two genes that ... providing data to support a new investigational treatment that ... Tony Godfrey, Ph.D., a research associate professor of Surgery ... was published by the journal Clinical Cancer Research. ...
... form of childhood cancer acute lymphoblastic leukemia are ... best efforts and the most powerful modern cancer drugs. ... the University of California, San Francisco have uncovered the basis ... use to stay alive. Targeting this protein may be the ...
Cached Medicine News:Health News:New report on health reform implementation: How to ensure access to coverage is maintained 2Health News:New report on health reform implementation: How to ensure access to coverage is maintained 3Health News:Smoking Raises Odds for Cancer in Women Already at High Risk 2Health News:Rep. Giffords to Get Skull Patch in Latest Step in Recovery 2Health News:Rep. Giffords to Get Skull Patch in Latest Step in Recovery 3Health News:End-of-Life Care Differs Between U.S., Canada, Study Finds 2Health News: Researchers home in on genetic signature of esophageal cancer 2Health News: Researchers home in on genetic signature of esophageal cancer 3Health News:UCSF team discovers key to fighting drug-resistant leukemia 2Health News:UCSF team discovers key to fighting drug-resistant leukemia 3
... Insta Test is an immunochromatography ... It is designed for qualitative ... specimens. The presence of myoglobin ... or higher can be detected ...
This advanced digital monitor detects the appearance of an irregular heartbeat during measurement and gives a warning signal with your reading. An irregular heartbeat may cause or indicate cardiovasc...
... (PSA) is a serine protease that is found ... of the acini and ducts. Normal PSA concentration ... Reports have suggested that elevated level of whole ... tumor markers in diagnosis of prostate cancers. InstaTest ...
... 25-Hydroxyvitamin D Assay is for use only ... Nichols Advantage® 25-Hydroxyvitamin D Assay is intended ... (25-OH-D) and other hydroxylated metabolites of vitamin ... used as an aid in the assessment ...
Medicine Products: